Dyne Therapeutics, Inc.

# Dyne Therapeutics, Inc.

Dyne Therapeutics is a clinical-stage biotechnology company developing therapeutics for neuromuscular diseases. The company's pipeline focuses on muscle disorders including myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease, along with programs targeting rare skeletal muscle and cardiac and metabolic muscle conditions. The company employs a proprietary platform called FORCE designed to deliver disease-modifying therapeutics to affected tissues.

The company operates as a private clinical-stage entity without commercial revenue generation, as its pipeline candidates remain in development phases. Research and development activities, including preclinical studies and clinical trials, represent the primary operational focus. Dyne maintains its headquarters in Waltham, Massachusetts, with approximately 240 full-time employees supporting its drug discovery and development operations. The company was incorporated in Delaware in 2017 and is publicly listed on the Nasdaq.